What is the new CMS prior authorization rule?

Editorial team Published on

The Centers for Medicare & Medicaid Services (CMS) released a major proposed rule in April 2026—CMS-0062-P (Interoperability Standards and Prior Authorization for Drugs)—which expands previous federal requirements to prescription drugs.

This proposal builds upon the earlier 2024 final rule (CMS-0057-F), which targeted medical items and services.

Key Components of the Proposed Rule (CMS-0062-P)

  • Electronic Prior Authorization (ePA) for Drugs: Impacted payers must support electronic prior authorization for prescription drugs covered under both medical benefits and pharmacy benefits.
  • Standardized Technology:
    • Medical benefit drugs will use HL7® FHIR® (Fast Healthcare Interoperability Resources) APIs.
    • Pharmacy benefit drugs will use standard NCPDP (National Council for Prescription Drug Programs) standards (SCRIPT, Formulary & Benefit, and Real-Time Prescription Benefit).
  • Compliance Timeline: Most requirements are slated to take effect by October 1, 2027.
  • Public Reporting & Transparency: Payers must publicly report annual metrics, including approval and denial rates, appeal outcomes, decision timeframes, and API usage metrics.
  • Mandatory Denial Reasons: Payers are required to provide specific, documented reasons when a prior authorization request is denied.

Context: The 2026 Operational Deadlines (from CMS-0057-F)

Under the broader prior authorization reforms that took effect in 2026, impacted payers (including Medicare Advantage, Medicaid/CHIP, and Marketplace plans) are already bound to strict decision timeframes for medical items and services:

  • Expedited/Urgent requests: Decisions must be made within 72 hours.
  • Standard/Non-urgent requests: Decisions must be made within 7 calendar days (or 15 days for certain QHP issuers on federal exchanges).

What are the changes in CMS prior authorization for 2026?

Enacted under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), major prior authorization changes took effect on January 1, 2026, forcing impacted payers to dramatically speed up turnaround times and increase accountability.

⏱️ Faster Decision Timelines

  • Expedited requests: Must be resolved within 72 hours.
  • Standard requests: Must be resolved within 7 calendar days.
  • Applicability: Covers Medicare Advantage, Medicaid/CHIP, and Federal Exchange plans.

📝 Specific Denial Explanations

  • Transparent rationales: Payers must provide a specific, actionable reason for every denial.
  • Plain language: Vague rejections like "not medically necessary" are restricted.

📊 Public Reporting Metrics

  • Accountability: Payers must publicly publish prior authorization metrics.
  • Data points: Includes approval/denial ratios and average processing times.

💡 Proposed Drug Rule Additions (CMS-0062-P)

  • Prescription expansion: CMS proposed extending these fast timelines and e-prior-authorization mandates to prescription drugs.
  • Technology upgrade: Pushes for widespread adoption of HL7 FHIR standards ahead of upcoming 2027 technical enforcement.

What are the current CMS prior authorization guidelines?

Current CMS (Centers for Medicare & Medicaid Services) prior authorization guidelines require major health plans to meet faster decision timeframes and prepare for full electronic automation.

Key Decision Timeframes (Active Now)

Under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), impacted payers (including Medicare Advantage, state Medicaid/CHIP agencies, and exchange Qualified Health Plans) must adhere to strict turnaround times for medical items and services:

  • Expedited (Urgent) Requests: Decisions must be provided within 72 hours.
  • Standard (Non-Urgent) Requests: Decisions must be provided within 7 calendar days (down from previous 14-day limits).
  • Detailed Denials: If a plan denies a medical service, they are legally required to provide a specific, documented reason for the denial and outline how to appeal.

Upcoming Electronic Requirements (2027)

  • API Implementation: Starting January 1, 2027, regulated health plans must implement and maintain Fast Healthcare Interoperability Resources (FHIR)-based Application Programming Interfaces (APIs) to streamline electronic prior authorizations.
  • Reduced Burden: The rules aim to cut down administrative back-and-forth by digitizing the process between providers, electronic health records (EHRs), and payers.

Proposed Rules for Prescription Drugs (CMS-0062-P)

CMS issued a proposed rule (CMS-0062-P) to expand these rapid, electronic, and transparent prior authorization standards over to prescription drugs (covering Medicare Advantage, Medicaid, CHIP, and marketplace plans) with proposed compliance deadlines scaling toward late 2027.

What are the key changes in the CMS new patient guidelines for 2026?

The Centers for Medicare & Medicaid Services (CMS) 2026 updates focus heavily on modernized care management, short-duration monitoring flexibility, and payment accuracy rather than a distinct overhaul of "new patient" office visit definitions.

Key 2026 CMS Policy & Billing Changes

  • Short-Duration Remote Monitoring: CMS introduced new short-duration codes for Remote Patient Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) to accommodate patient engagement lasting less than traditional 16-day minimum thresholds.
  • Care Management Alignment: The update better links primary and behavioral health through revised add-on structures and clarifies that specific care management services also qualify as care coordination for billing.
  • Clinic and Center Billing Updates: Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs) must transition away from retired general codes (like G0512) and report individual CPT/HCPCS codes for specific services.
  • Skin Substitutes Reclassification: Reclassifying skin substitutes as "incident-to" supplies under the Physician Fee Schedule significantly cuts waste and shifts non-facility billing rules.
  • Prevention and Wellness: CMS repurposed risk assessment codes for physical activity and nutrition while adding new chronic disease prevention measures.

What is the new CMS rule?

The Centers for Medicare & Medicaid Services (CMS) has recently issued several major new rules across Medicare, Medicaid, and insurance marketing, most notably the finalization of the GLOBE Model mandatory drug payment initiative.

Major Recent CMS Rules

  • GLOBE Model (Drug Payment): CMS finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory Part B payment model starting January 1, 2027, designed to lower prescription drug costs for Original Medicare beneficiaries.
  • Medicare Advantage & Part D Marketing Changes: Effective October 1, 2026, CMS relaxed five marketing rules for insurance agents—including eliminating the 48-hour cool-off period between initial client contact and plan discussions, and shortening sales call recording retention from 10 years to 6 years.
  • Medicaid Community Engagement: Issued an interim final rule requiring certain adults in Medicaid to fulfill 80 hours per month of work or community engagement, with state implementation required by January 1, 2027.
  • Phasing Out Fax/Mail: A rule finalized earlier in the year phases out paper mail and fax machines for specific HIPAA-related claims attachments and electronic signatures, targeting mandatory compliance by May 2028.

CMS 2026 Prior Authorization Proposed Rule

9 related questions found

What are major changes to Medicare in 2026?

Major changes to Medicare in 2026 include a Part D out-of-pocket spending cap of $2,100, lower negotiated prices on initial high-cost prescription drugs, and standard Part B premium increases.

You can review comprehensive cost breakdowns and updates directly through the Official Medicare Costs Publication.

Prescription Drug and Part D Updates

  • Out-of-Pocket Cap: The annual maximum out-of-pocket spending limit for Part D prescription medications increases to $2,100 (up from $2,000 in 2025).
  • Negotiated Drug Prices: The first round of lower prices from the Medicare Drug Price Negotiation program takes effect for 10 high-cost drugs.
  • Payment Plan Auto-Renewal: Enrollees in the Medicare Prescription Payment Plan are automatically re-enrolled unless they opt out, allowing them to spread pharmacy costs evenly across the year.
  • Part D Deductible: The maximum allowable Part D deductible rises to $615.

Premiums, Deductibles, and Costs

  • Part B Standard Premium: The standard monthly premium for Medicare Part B rises to $202.90.
  • Part B Annual Deductible: The Part B deductible increases to $283.
  • Part A Inpatient Deductible: The Part A deductible for inpatient hospital care increases to $1,736 per benefit period.

Medicare Advantage and Program Pilots

  • Out-of-Pocket Limit: The maximum in-network out-of-pocket limit for Medicare Advantage plans slightly decreases to $9,250.
  • Prior Authorization Pilot: Original Medicare launches a prior authorization pilot program in six states for specific Part B items and services.
  • Supplemental Benefits Restrictions: CMS tightened rules on non-health-related Special Supplemental Benefits for the Chronically Ill (SSBCI), excluding items like non-healthy foods, alcohol, tobacco, and cosmetics.
  • Directory Protection: A special enrollment period is available for beneficiaries who select a Medicare Advantage plan using online tools with inaccurate provider directories.

What are three drugs that require prior authorization?

Many health insurance plans require prior authorization (pre-approval from the insurance company before they will cover the cost) for specialty, high-cost, or controlled medications. Three common examples of drugs that frequently require prior authorization include:

  • Ozempic (semaglutide): Often prescribed for type 2 diabetes, insurers frequently require prior authorization to ensure it is being used for an approved medical condition rather than off-label cosmetic weight loss, or to verify that step therapy requirements (trying preferred alternatives first) have been met.
  • Botox (onabotulinumtoxinA): While widely known for cosmetic use, therapeutic applications like chronic migraine prevention, severe muscle spasticity, or bladder dysfunction routinely require prior authorization from insurance to confirm medical necessity.
  • Humira (adalimumab): As an expensive biologic medication used for chronic inflammatory conditions like rheumatoid arthritis or Crohn's disease, plans require prior authorization to verify diagnosis criteria and ensure patients have tried standard first-line treatments (such as traditional nonsteroidal anti-inflammatory drugs or methotrexate) without success.

Is Medicare going to start requiring prior authorizations?

Yes, Original Medicare is introducing prior authorization requirements for certain specific outpatient services and items as part of a pilot program that began on January 1, 2026.

How the New Rules Work

  • The WISeR Model: The Centers for Medicare & Medicaid Services (CMS) launched the Wasteful and Inappropriate Service Reduction (WISeR) pilot model to target services vulnerable to fraud, waste, and abuse.
  • Affected States: The pilot is active in six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington.
  • Targeted Services: It applies to 17 specific outpatient procedures, including:
    • Skin and tissue substitutes for chronic wounds
    • Cervical spine fusion surgery
    • Electrical nerve stimulators
    • Knee arthroscopy for osteoarthritis
    • Epidural steroid injections for pain management

What This Means for You

  • Traditional vs. Advantage: While Medicare Advantage plans have historically required prior authorization for a wide array of care, Original (Traditional) Medicare still does not require pre-approval for most routine or emergency medical services.
  • If You Live in a Pilot State: If you have Original Medicare and live in one of the six participating states, your doctor must request pre-approval before performing any of the specific targeted procedures, or coverage may be denied.

What's the difference between precertification and prior authorization?

While many health insurance companies use precertification and prior authorization interchangeably, some medical billing offices draw a subtle operational distinction between the two based on the type of care.

Key Differences

  • Interchangeable Usage: The American Medical Association (AMA) and most major health plans treat both terms as the exact same advance-approval process required before a service is delivered.
  • Precertification Focus: When separated operationally, precertification usually verifies that a planned service, facility stay, or inpatient admission is a covered benefit under the patient's specific health plan.
  • Prior Authorization Focus: Prior authorization (or preauthorization) typically involves a deeper clinical review to establish the strict medical necessity of a specific outpatient test, specialty drug, or advanced procedure.
  • Type of Service: Precertification is more commonly tied to inpatient hospital admissions, rehab stays, or facility surgeries, whereas prior authorization is frequently required for outpatient imaging (like MRIs), costly specialty medications, and specific treatments.

Can I do my own prior authorization?

You generally cannot do a complete prior authorization yourself because it requires clinical notes and medical justification from your doctor, though some insurance plans allow you to submit certain forms or file appeals on your own behalf.

Why Doctors Must Start the Process

  • Medical records: Insurance companies require specific clinical notes, diagnosis codes, and treatment histories that only your doctor's office can provide.
  • Prescriber rules: Most health plans mandate that a licensed healthcare professional initiate medical and prescription pre-approvals.

When You Can Take Action

  • Submitting forms: Certain insurers or Medicare Part D plans let patients fill out and submit specific coverage determination request forms directly.
  • Filing appeals: You are allowed to file an appeal on your own if a prior authorization is denied, though it is still best to coordinate with your doctor.
  • Checking status: You can call the member services number on your insurance card to track a request or see if a drug requires approval.

You can check your specific plan's rules through Blue Shield of California or your own insurer's member portal.